The main objective of this study was to evaluate progression-free and overall survival (PFS and OS) depending on the extent of resection (EOR) and adjuvant treatment in the largest contemporary cohort of IDH-wt astrocytoma formerly classified as WHO grade II-III. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).